Literature DB >> 16187196

The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard dose anti-reflux medications.

Jimmy M Bautista1, Wai-Man Wong, Gloria Pulliam, Romeo F Esquivel, Ronnie Fass.   

Abstract

To determine the value of pH testing in clinical practice in gastroesophageal reflux disease patients who failed anti-reflux treatment. Patients resistant to standard dose proton pump inhibitor or an H2-blocker underwent pH testing. Randomly selected patients from the proton pump inhibitor failure group underwent the modified acid perfusion test as compared to patients with non-erosive reflux disease. In the proton pump inhibitor failure group (n = 70), 63.8% had a normal pH test as compared to 29% in the H2-blocker group (n = 31) (P = 0.007). Sensory intensity rating and acid perfusion sensitivity score were significantly higher in the non-erosive reflux disease control group than the proton pump inhibitor failure group (P < 0.05). Most patients who continued to be symptomatic on proton pump inhibitor once daily demonstrated a normal pH test and overall lack of increased chemoreceptor sensitivity to acid.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187196     DOI: 10.1007/s10620-005-2960-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

Review 1.  Gastroesophageal reflux disease revisited.

Authors:  Ronnie Fass
Journal:  Gastroenterol Clin North Am       Date:  2002-12       Impact factor: 3.806

2.  Assessment of relationship between acid reflux and heartburn using receiver operating characteristic curves.

Authors:  Joseph Steinbach; Ronnie Fass; Ravinder K Mittal
Journal:  Gastroenterol Clin North Am       Date:  2002-12       Impact factor: 3.806

3.  Is gastric acid hypersecretion the only reason for refractory gastroesophageal reflux disease?

Authors:  V Savarino; G S Mela; P Zentilin; G Celle
Journal:  Gastroenterology       Date:  1990-11       Impact factor: 22.682

4.  Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.

Authors:  C P Dekkers; J A Beker; B Thjodleifsson; A Gabryelewicz; N E Bell; T J Humphries
Journal:  Aliment Pharmacol Ther       Date:  1999-01       Impact factor: 8.171

5.  High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.

Authors:  P J Kahrilas; M B Fennerty; B Joelsson
Journal:  Am J Gastroenterol       Date:  1999-01       Impact factor: 10.864

6.  The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.

Authors:  R Fass; J J Ofman; R E Sampliner; L Camargo; C Wendel; M B Fennerty
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

Review 7.  Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease.

Authors:  Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

8.  Omeprazole as a diagnostic tool in gastroesophageal reflux disease.

Authors:  B E Schenk; E J Kuipers; E C Klinkenberg-Knol; H P Festen; E H Jansen; H A Tuynman; M Schrijver; L A Dieleman; S G Meuwissen
Journal:  Am J Gastroenterol       Date:  1997-11       Impact factor: 10.864

9.  A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial.

Authors:  J Mössner; A H Hölscher; R Herz; A Schneider
Journal:  Aliment Pharmacol Ther       Date:  1995-06       Impact factor: 8.171

10.  Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.

Authors:  M L Cloud; W W Offen; M Robinson
Journal:  Am J Gastroenterol       Date:  1991-12       Impact factor: 10.864

View more
  9 in total

Review 1.  Diagnosis and Management of Functional Heartburn.

Authors:  Christine Hachem; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

2.  A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough.

Authors:  Xianghuai Xu; Hanjing Lv; Li Yu; Qiang Chen; Siwei Liang; Zhongmin Qiu
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

Review 3.  Advancements in the analysis of esophageal pH monitoring in GERD.

Authors:  Tiberiu Hershcovici; Anita Gasiorowska; Ronnie Fass
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 4.  Management of refractory typical GERD symptoms.

Authors:  Emidio Scarpellini; Daphne Ang; Ans Pauwels; Adriano De Santis; Tim Vanuytsel; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-14       Impact factor: 46.802

5.  Heartburn refractory to proton-pump inhibitors.

Authors:  Apurva Trivedi; John D Long
Journal:  Curr Treat Options Gastroenterol       Date:  2007-02

Review 6.  Diagnostic options for patients with refractory GERD.

Authors:  Fernando Fornari; Daniel Sifrim
Journal:  Curr Gastroenterol Rep       Date:  2008-06

7.  Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy.

Authors:  George Karamanolis; Tim Vanuytsel; Daniel Sifrim; Raf Bisschops; Joris Arts; Philip Caenepeel; Dominiek Dewulf; Jan Tack
Journal:  Dig Dis Sci       Date:  2008-03-06       Impact factor: 3.199

8.  Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec.

Authors:  Dave Walker; Richard Ng Kwet Shing; Deborah Jones; Hans-Jurgen Gruss; Jarosław Reguła
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

9.  The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum.

Authors:  Zilla H Hussain; Emily E Henderson; Carla Maradey-Romerao; Nina George; Ronnie Fass; Brian E Lacy
Journal:  Clin Transl Gastroenterol       Date:  2015-08-13       Impact factor: 4.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.